To 'Infinity' and Beyond: $150M to Propel PI3K Inhibitor IPI-145
By Marie Powers
Friday, December 14, 2012
Four months after raising $76.85 million in an underwritten public offering, Infinity Pharmaceuticals Inc. went back for a heaping plate of seconds, seeking to raise $150 million by pricing an offering of 5.7 million shares of common stock at $26.33 apiece.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.